Drugs / SY-009
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04345107 | May 2020 → Apr 2021 | type 2 diabetes mellitus | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04119947 | Mar → May 2019 | diabetes mellitus | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05426018 | Jul 2022 → Jun 2023 | type 2 diabetes mellitus | Suzhou Yabao Pharmaceutical R&D Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SY009 | “Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus.” PMID 39936104 ↗ Jan 2025 |
| Action | Inhibit | “SY-009 produces a hypoglycemic effect via inhibiting sodium/glucose cotransporter 1 (SGLT1) in type 2 diabetes mellitus (T2DM) patients.” PMID 37981049 ↗ Nov 2023 |
| Route | Oral | “A single dose of SY-009 (0.5-40mg) taken orally.” NCT04119947 ↗ |